Congressional Research Service LSB10010
All Eyes on Allergan: Drug Company’s Unprecedented Move Raises Questions for Patent and Drug Law (Part II)
Source-supplied metadata for version 4, published Oct 12, 2017.
Source-supplied fields
Report metadata
- Identifier
- LSB10010
- Version
- 4
- Product type
- Posts
- Status
- Archived
- Published
- Oct 12, 2017
- Source updated
- Jun 21, 2025, 3:19 am UTC
Politically.com intentionally does not reproduce the report summary or full text. Use the official Congress.gov links above to read the product in its source context.
Structured Congress.gov references
Related federal bills
No structured bill reference is present in the hydrated Congress.gov metadata cache.